Jenna Burton
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 25 | 2025 | 140 | 6.550 |
Why?
| | Cat Diseases | 6 | 2023 | 37 | 2.170 |
Why?
| | Dogs | 30 | 2025 | 517 | 1.890 |
Why?
| | Osteosarcoma | 7 | 2025 | 100 | 1.040 |
Why?
| | Neoplasms | 6 | 2024 | 2954 | 1.020 |
Why?
| | Lymphoma | 3 | 2024 | 251 | 0.970 |
Why?
| | Cancer Vaccines | 2 | 2025 | 161 | 0.910 |
Why?
| | Bone Neoplasms | 6 | 2025 | 272 | 0.850 |
Why?
| | Doxorubicin | 5 | 2024 | 416 | 0.830 |
Why?
| | Prednisone | 4 | 2024 | 229 | 0.820 |
Why?
| | Antineoplastic Agents | 7 | 2018 | 2219 | 0.780 |
Why?
| | Cyclophosphamide | 4 | 2024 | 275 | 0.630 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2018 | 20 | 0.560 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2018 | 35 | 0.540 |
Why?
| | Cats | 6 | 2023 | 226 | 0.530 |
Why?
| | Animals | 35 | 2025 | 38106 | 0.530 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 141 | 0.520 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2018 | 196 | 0.500 |
Why?
| | Lomustine | 2 | 2024 | 18 | 0.500 |
Why?
| | Lymphoma, B-Cell | 1 | 2018 | 150 | 0.500 |
Why?
| | Mastectomy | 1 | 2018 | 189 | 0.490 |
Why?
| | Prostatic Neoplasms | 2 | 2022 | 972 | 0.470 |
Why?
| | Ultrasonography | 1 | 2019 | 788 | 0.450 |
Why?
| | Mastocytosis | 1 | 2015 | 15 | 0.440 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2015 | 76 | 0.430 |
Why?
| | Veterinary Medicine | 1 | 2014 | 12 | 0.420 |
Why?
| | Pyrroles | 1 | 2015 | 222 | 0.400 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1064 | 0.380 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1998 | 0.360 |
Why?
| | Tongue Neoplasms | 1 | 2012 | 27 | 0.360 |
Why?
| | Hemangiosarcoma | 1 | 2012 | 27 | 0.360 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2015 | 429 | 0.350 |
Why?
| | Mouth Neoplasms | 2 | 2023 | 88 | 0.330 |
Why?
| | Indoles | 1 | 2015 | 511 | 0.330 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2011 | 415 | 0.330 |
Why?
| | Adenocarcinoma | 1 | 2018 | 927 | 0.330 |
Why?
| | Vincristine | 3 | 2024 | 148 | 0.310 |
Why?
| | Soft Tissue Neoplasms | 1 | 2011 | 133 | 0.300 |
Why?
| | Sarcoma | 1 | 2011 | 209 | 0.280 |
Why?
| | Pets | 2 | 2021 | 28 | 0.270 |
Why?
| | Interleukin-15 | 2 | 2025 | 96 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-kit | 2 | 2017 | 73 | 0.230 |
Why?
| | Listeria | 1 | 2025 | 5 | 0.220 |
Why?
| | Drug Administration Schedule | 4 | 2016 | 790 | 0.220 |
Why?
| | Melanoma | 2 | 2022 | 765 | 0.210 |
Why?
| | Treatment Outcome | 11 | 2025 | 11821 | 0.210 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1036 | 0.200 |
Why?
| | Chlorambucil | 1 | 2022 | 11 | 0.190 |
Why?
| | Gastrointestinal Absorption | 1 | 2022 | 6 | 0.190 |
Why?
| | Retrospective Studies | 10 | 2024 | 17438 | 0.180 |
Why?
| | Leiomyosarcoma | 1 | 2022 | 30 | 0.180 |
Why?
| | Area Under Curve | 1 | 2022 | 335 | 0.170 |
Why?
| | Leiomyoma | 1 | 2022 | 62 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2025 | 429 | 0.170 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2022 | 88 | 0.170 |
Why?
| | Prostatic Hyperplasia | 1 | 2021 | 40 | 0.170 |
Why?
| | Male | 15 | 2025 | 73396 | 0.160 |
Why?
| | Maximum Tolerated Dose | 2 | 2018 | 217 | 0.160 |
Why?
| | Carcinoma | 1 | 2021 | 225 | 0.150 |
Why?
| | Administration, Oral | 1 | 2022 | 872 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 122 | 0.150 |
Why?
| | Cystectomy | 1 | 2019 | 46 | 0.150 |
Why?
| | Sirolimus | 1 | 2021 | 282 | 0.150 |
Why?
| | Education, Veterinary | 1 | 2019 | 7 | 0.150 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2019 | 70 | 0.150 |
Why?
| | Kinetics | 1 | 2022 | 1553 | 0.140 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 747 | 0.140 |
Why?
| | Embolization, Therapeutic | 1 | 2021 | 246 | 0.140 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2018 | 15 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1160 | 0.140 |
Why?
| | Female | 13 | 2025 | 79499 | 0.140 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 370 | 0.140 |
Why?
| | Carboplatin | 2 | 2021 | 168 | 0.140 |
Why?
| | Authorship | 1 | 2019 | 51 | 0.140 |
Why?
| | Curcumin | 1 | 2018 | 29 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2023 | 628 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2023 | 563 | 0.130 |
Why?
| | Catheter Ablation | 1 | 2021 | 355 | 0.130 |
Why?
| | Prevalence | 1 | 2024 | 2861 | 0.130 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 419 | 0.130 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2017 | 6 | 0.130 |
Why?
| | Bone Marrow | 1 | 2018 | 310 | 0.120 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 259 | 0.120 |
Why?
| | Liposomes | 1 | 2018 | 269 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 970 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2022 | 776 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 447 | 0.110 |
Why?
| | Interferon Regulatory Factors | 1 | 2015 | 45 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 237 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2016 | 157 | 0.110 |
Why?
| | Prospective Studies | 5 | 2024 | 8123 | 0.110 |
Why?
| | Vaccination | 1 | 2023 | 1449 | 0.110 |
Why?
| | Benzamides | 1 | 2016 | 226 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2018 | 399 | 0.110 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 287 | 0.110 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 195 | 0.100 |
Why?
| | Uveitis | 1 | 2015 | 152 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1432 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1031 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2022 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 467 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 2 | 2025 | 585 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3926 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2019 | 2012 | 0.080 |
Why?
| | Combined Modality Therapy | 2 | 2025 | 1271 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4580 | 0.080 |
Why?
| | Immunophenotyping | 1 | 2011 | 324 | 0.080 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 693 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2675 | 0.070 |
Why?
| | Biopsy | 1 | 2011 | 1075 | 0.070 |
Why?
| | Prognosis | 2 | 2017 | 4351 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2011 | 1163 | 0.060 |
Why?
| | Cohort Studies | 2 | 2019 | 6077 | 0.060 |
Why?
| | Lymph Nodes | 2 | 2020 | 511 | 0.060 |
Why?
| | Pilot Projects | 1 | 2011 | 1888 | 0.060 |
Why?
| | Asparaginase | 1 | 2024 | 34 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2010 | 931 | 0.050 |
Why?
| | Tetrachlorvinphos | 1 | 2023 | 1 | 0.050 |
Why?
| | Alanine | 1 | 2024 | 171 | 0.050 |
Why?
| | Purines | 1 | 2024 | 188 | 0.050 |
Why?
| | Epidemiologic Studies | 1 | 2023 | 70 | 0.050 |
Why?
| | Cytokines | 2 | 2025 | 2081 | 0.050 |
Why?
| | Desmin | 1 | 2022 | 22 | 0.040 |
Why?
| | Absorbable Implants | 1 | 2022 | 38 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1361 | 0.040 |
Why?
| | Microspheres | 1 | 2022 | 142 | 0.040 |
Why?
| | Laminin | 1 | 2022 | 72 | 0.040 |
Why?
| | Retroperitoneal Space | 1 | 2021 | 19 | 0.040 |
Why?
| | Mast Cells | 1 | 2023 | 150 | 0.040 |
Why?
| | Aggression | 1 | 2023 | 171 | 0.040 |
Why?
| | Microwaves | 1 | 2021 | 29 | 0.040 |
Why?
| | Prostate | 1 | 2022 | 159 | 0.040 |
Why?
| | Paclitaxel | 1 | 2022 | 260 | 0.040 |
Why?
| | Therapies, Investigational | 1 | 2021 | 18 | 0.040 |
Why?
| | Urinary Bladder | 1 | 2022 | 194 | 0.040 |
Why?
| | Arteries | 1 | 2021 | 261 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2020 | 210 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2020 | 164 | 0.040 |
Why?
| | PAX5 Transcription Factor | 1 | 2019 | 15 | 0.040 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 13 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 335 | 0.040 |
Why?
| | Quality of Life | 1 | 2011 | 3200 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2018 | 90 | 0.030 |
Why?
| | Bibliometrics | 1 | 2019 | 68 | 0.030 |
Why?
| | Polymers | 1 | 2022 | 488 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 209 | 0.030 |
Why?
| | Medical Oncology | 1 | 2021 | 345 | 0.030 |
Why?
| | Humans | 7 | 2025 | 146342 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2021 | 455 | 0.030 |
Why?
| | Publishing | 1 | 2019 | 117 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 344 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2867 | 0.030 |
Why?
| | Periodicals as Topic | 1 | 2019 | 214 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2092 | 0.030 |
Why?
| | Retinal Neurons | 1 | 2015 | 4 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1998 | 0.030 |
Why?
| | Electroretinography | 1 | 2015 | 51 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1712 | 0.030 |
Why?
| | Th17 Cells | 1 | 2015 | 103 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 139 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 385 | 0.020 |
Why?
| | Cell Movement | 1 | 2018 | 951 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 2020 | 806 | 0.020 |
Why?
| | Extremities | 1 | 2014 | 142 | 0.020 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2016 | 220 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 416 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2107 | 0.020 |
Why?
| | Research Design | 1 | 2019 | 1143 | 0.020 |
Why?
| | Retina | 1 | 2015 | 330 | 0.020 |
Why?
| | Microglia | 1 | 2015 | 289 | 0.020 |
Why?
| | Phosphorylation | 1 | 2017 | 1724 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 508 | 0.020 |
Why?
| | Mice | 2 | 2022 | 18297 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2786 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 3545 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2016 | 1339 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1150 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 10921 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3125 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5246 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2921 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4340 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2113 | 0.010 |
Why?
| | United States | 1 | 2021 | 16136 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2418 | 0.010 |
Why?
|
|
Burton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|